Posted by Michael Wonder on 01 Aug 2018
Institute for Clinical and Economic Review posts draft scoping document on canakinumab for atherosclerosis
1 August 2018 - Document open to public comment until August 22, 2018.
The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. The scoping document will be open to public comment until 5 pm ET on 22 August 2018.
Canakinumab was originally approved by the FDA in 2009 and is marketed for various rare inflammatory disorders; it is currently under review for a new indication in atherosclerosis. ICER’s report on canakinumab will be the subject of a February 2019 meeting of the California Technology Assessment Forum (CTAF), one of ICER’s three independent evidence appraisal committees.
